Huntington Hospital recently hosted a clinical trial for a dual-chamber leadless pacemaker system. We’re excited to announce that the findings were published in the New England Journal of Medicine (NEJM). The study was helmed by Huntington physician Mayer Rashtian, MD, FACC, FHRS, (principal investigator) with support from his partners and our clinical research nurses. Thanks to a great recruitment effort from Dr. Rashtian and our outstanding team, Huntington was one of the top clinical trial enrollers in the world.
The pacemaker system, which consists of two implanted devices, one in the right atrium and another in the right ventricle, makes leadless pacemaker therapy a treatment option for a wider range of indications, such as consistent atrioventricular synchrony. During the trial, the team coordinated the dual-chamber leadless pacemakers implants, collected/reported data and ensured a good patient experience.
The dual-chamber leadless pacemaker system is now FDA approved. To learn more about the study, visit NEJM.